Zydus Lifesciences shares bounce 6% on buyback buzz; co proclaims $166 mn Assertio acquisition
Zydus Lifesciences shares climbed to an intraday excessive of Rs 993.80 on Thursday. The inventory is up about 8% over the previous month and 10% over the previous yr. Over the long run, Zydus Lifesciences has delivered a 93% return in three years and almost 61% over 5 years.
Zydus Lifesciences share buyback
In an trade submitting launched on Wednesday, Zydus Lifesciences introduced that its board of administrators will meet on Might 19 to think about and approve its outcomes for the January-March quarter of the monetary yr 2026. Together with the earnings, the board may also think about a proposal to purchase again absolutely paid-up fairness shares of the corporate, it additional mentioned.
This comes after Zydus Lifesciences’ Rs 600 crore share buyback at a worth of Rs 1,005 apiece through the tender route. The buyback worth implied a premium of almost 9% from the extent at which the inventory was buying and selling on the document date. Earlier than that, the corporate executed a Rs 750-crore share buyback in 2022.
Zydus Lifesciences proclaims acquisition of Assertio Holdings
Zydus Lifesciences on Wednesday introduced that it has entered into an settlement to accumulate US-based pharma firm Assertio Holdings for $166.40 million. Assertio is concentrated on speciality and oncology supportive-care therapies.
“Zydus Worldwide DMCC, a subsidiary of the corporate, has signed a definitive settlement, by its wholly owned acquisition subsidiary Zara Merger Sub Inc, with Assertio Holdings to accumulate all excellent shares of Assertio for $23.50 per share in money,” in keeping with the assertion.
Additionally learn: NLC India shares rally 18% to recent document excessive after This autumn web revenue skyrockets 189% YoYThis comes after The Financial Occasions reported that Zydus Lifesciences is near buying a US-based drugmaker. Sources within the funding banking circles instructed ET that Zydus will get a lift because the goal firm has its personal pipeline of biologic medicine. For a number of months, Zydus Lifesciences has been taking a look at methods to develop its pipeline of revolutionary medicine. It was additionally seen in discussions with Ardelyx a number of months in the past, however the talks didn’t materialise. “Zydus has been in discussions with a minimum of three corporations,” the supply talked about.
(Disclaimer: Suggestions, recommendations, views and opinions given by the consultants are their very own. These don’t signify the views of The Financial Occasions)
